PD-L1/PD1 Modulation Mechanisms in Lung Cancer: From Basic to Translational Evidences

Dear Colleagues,

Despite all recent efforts, the complex and dynamic interactions between immune systems and tumors allow us to understand why predicting the response of immune checkpoint inhibitors (ICIs) treatment using a single biomarker might not be possible in lung cancer. The predictive and prognostic values of the PD-L1 expression alone in lung cancer patients is currently under debate because of the methodological assessment of the PD-L1 expression and its temporal variations. Better detailed studies aimed at understanding the molecular basis of the main immunotherapy biomarkers are in demand. Genetic and epigenetic alterations strictly linked to the CD274/PD-L1 and CD279/PD-1 gene modulations have received surprisingly little attention until now, even if the results are currently highlighting the power of this analysis.

In this Special Issue, we plan to focus on genetic and epigenetic alterations that have a significant impact on the PD-L1/PD-1 system in solid tumors. We will discuss their biologic mechanism, detection methodologies, their impact on patients’ outcomes and utility in the context of immunotherapy in the cancer scenario.

Dr. Lucia Anna Muscarella
Dr. Umberto Malapelle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.